Accuron MedTech Group (AMT) officially opens a new tech centre in Singapore dedicated to facilitating synergies across the company’s portfolio and accelerating commercialisation for Southeast Asia’s healthcare ventures, helping them in reaching global market.
The 22,000 square-foot construction is located in Tuas, next to the global headquarters of AMT. The facilities available are to support AMT’s portfolio companies with research, development, manufacturing capabilities such as rapid prototyping, turnkey manufacturing, cleanroom manufacturing and assembly, 3D printing, and medical device sterilisation, as well as commercial activities such as R&D, finance, HR, and business development.
AWAK Technologies is one portfolio company that has moved its operation to the centre is. It is a medical technology company focused on dialysis using regeneration technology for end-stage renal disease.
“The Technology Centre enables us to accelerate our plans for the future to identify and nurture high-quality category-disruptive technologies in Singapore and South-East Asia,” said Abel Ang, Group Chief Executive of Accuron MedTech.
All of Accuron MedTech’s investee companies will have access to Accuron MedTech’s senior management team, which has more than 100+ years of international healthcare sector expertise, taking medical innovations from concept phase through to commercialisation worldwide.
In the last four years, Accuron MedTech has done more than 10 strategic transactions, including investments in renal companies AWAK Technologies and Advent Access, and NASDAQ-listed ASLAN Pharmaceuticals.
Earlier in 2018, Accuron MedTech announced a co-investment of S$20 million together with SEEDS Capital, the investment arm of Enterprise Singapore, to identify and catalyse the growth of high-potential Singapore-based start-ups.